FEM-3 Inhibitors
FEM-3 inhibitors belong to a class of chemical compounds specifically designed to modulate the activity of the FEM-3 kinase enzyme. FEM-3, also known as tyrosine kinase-like orphan receptor 2 (PTK7), is a member of the receptor tyrosine kinase (RTK) family. These inhibitors are developed to selectively target and inhibit the catalytic activity of the FEM-3 kinase, thereby interfering with its function in cellular signaling pathways. The chemical structures of FEM-3 inhibitors can vary widely, ranging from small molecules to larger compounds. Researchers use various approaches, such as high-throughput screening and structure-based design, to identify and develop these inhibitors. The goal is to find compounds that can specifically interact with the active site of FEM-3 and disrupt its kinase activity.
The discovery and study of FEM-3 inhibitors have provided valuable insights into the role of FEM-3 in cellular processes. By selectively targeting FEM-3, researchers can investigate its precise role in cellular signaling, cell growth, and differentiation. These inhibitors serve as powerful tools to dissect the function of FEM-3 and its impact on various physiological and pathological conditions. The use of FEM-3 inhibitors offers significant potential in understanding the intricate mechanisms of RTK signaling and its role in cellular development and homeostasis. By inhibiting FEM-3 kinase activity, researchers can uncover the downstream targets and pathways regulated by FEM-3, contributing to a more comprehensive understanding of its biological functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NVP-BHG712 | 940310-85-0 | sc-364554 sc-364554A | 5 mg 50 mg | $232.00 $1764.00 | ||
NVP-BHG712 is a selective inhibitor of the tyrosine kinase receptor EphB4, which has been shown to inhibit fem-3 kinase activity. | ||||||
AZD1208 | 1204144-28-4 | sc-503188 | 10 mg | $322.00 | 1 | |
AZD1208 is a multi-targeted inhibitor with activity against multiple protein kinases, including fem-3 | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
AP 24534 is a potent multi-targeted kinase inhibitor, primarily known for its activity against BCR-ABL, which is involved in chronic myeloid leukemia. It has also been reported to inhibit fem-3 kinase activity. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
VX-680 is a small-molecule inhibitor that targets multiple kinases, including fem-It has been studied in research models for its potential as an anti-cancer agent. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM 447439 is a selective Aurora kinase inhibitor that has been shown to inhibit fem-3 kinase activity. It has been studied for its effects on cell cycle regulation and cancer cell growth. | ||||||
SU 4312 | 5812-07-7 | sc-200637 sc-200637A | 5 mg 25 mg | $99.00 $367.00 | 2 | |
SU4312 is a small-molecule inhibitor that primarily targets the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases. It has also been reported to inhibit fem-3 kinase activity. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is a selective inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinase, but it has also been reported to inhibit fem-3 kinase activity. | ||||||
TG101209 | 936091-14-4 | sc-364731 sc-364731A | 5 mg 50 mg | $255.00 $1455.00 | ||
TG101209 is a small-molecule inhibitor that primarily targets Janus kinase 2 (JAK2), but it has also been reported to inhibit fem-3 kinase activity. It has been investigated for its potential in myeloproliferative neoplasms. | ||||||